Transforming the Future of Chronic Kidney Disease Treatment

Preserving Kidney Function in
Patients at High Risk of Kidney Failure

ProKidney (NASDAQ: PROK) is a late-clinical-stage biotechnology company pioneering a novel autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) at high risk of kidney failure, a population with limited treatment options beyond preparing for dialysis or kidney transplant.

LATE-STAGE PIPELINE

Rilparencel is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study to assess its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.

LEARN MORE

ADDRESSING A HIGH UNMET NEED

Over 35 million U.S. adults have CKD with approximately 135,000 patients progressing to dialysis every year. Therapeutic options to delay the need for dialysis in patients with advanced CKD at high risk of kidney failure are limited. While approved therapies for patients with CKD have been shown to delay disease progression in some patients, many continue to lose kidney function. Management of patients in Stage 4 CKD is largely focused on addressing their comorbidities and preparing them for dialysis.